| | |
| Clinical data | |
|---|---|
| Other names | 5-TME; 3-Ethoxy-4-methoxy-5-methylthiophenethylamine; 3-EtO-4-MeO-5-MeS-PEA |
| Routes of administration | Oral [1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C12H19NO2S |
| Molar mass | 241.35 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5-Thiometaescaline (5-TME), also known as 3-ethoxy-4-methoxy-5-methylthiophenethylamine, is a psychoactive drug of the phenethylamine and scaline families related to mescaline. [1] [2] [3] It is the analogue of metaescaline in which the methoxy group at the 5 position has been replaced with a methylthio group. [1] [2] [3] The drug is one of three possible positional isomers of thiometaescaline (TME), the others being 3-thiometaescaline (3-TME) and 4-thiometaescaline (4-TME). [1] [2] [3]
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 5-TME's dose as greater than 200 mg orally and its duration as unknown. [1] [2] The effects of 5-TME have been reported to include possible tinnitus, a possible brush of lightheadedness, and nothing else, but these changes could not be clearly ascribed to the drug. [1]
The chemical synthesis of 5-TME has been described. [1] [3]
5-TME was first described in the scientific literature by Alexander Shulgin and Peyton Jacob III in 1984. [3] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991. [1]